Haemonetics Management
Management criteria checks 2/4
Haemonetics' CEO is Chris Simon, appointed in May 2016, has a tenure of 7.92 years. total yearly compensation is $10.69M, comprised of 9.5% salary and 90.5% bonuses, including company stock and options. directly owns 0.4% of the company’s shares, worth €16.34M. The average tenure of the management team and the board of directors is 3.4 years and 6.4 years respectively.
Key information
Chris Simon
Chief executive officer
US$10.7m
Total compensation
CEO salary percentage | 9.5% |
CEO tenure | 7.9yrs |
CEO ownership | 0.4% |
Management average tenure | 3.4yrs |
Board average tenure | 6.4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 30 2023 | n/a | n/a | US$127m |
Sep 30 2023 | n/a | n/a | US$128m |
Jul 01 2023 | n/a | n/a | US$137m |
Apr 01 2023 | US$11m | US$1m | US$115m |
Dec 31 2022 | n/a | n/a | US$96m |
Oct 01 2022 | n/a | n/a | US$86m |
Jul 02 2022 | n/a | n/a | US$68m |
Apr 02 2022 | US$9m | US$945k | US$43m |
Jan 01 2022 | n/a | n/a | US$23m |
Oct 02 2021 | n/a | n/a | US$31m |
Jul 03 2021 | n/a | n/a | US$64m |
Apr 03 2021 | US$9m | US$963k | US$79m |
Dec 26 2020 | n/a | n/a | US$108m |
Sep 26 2020 | n/a | n/a | US$106m |
Jun 27 2020 | n/a | n/a | US$96m |
Mar 28 2020 | US$9m | US$937k | US$77m |
Dec 28 2019 | n/a | n/a | US$80m |
Sep 28 2019 | n/a | n/a | US$68m |
Jun 29 2019 | n/a | n/a | US$49m |
Mar 30 2019 | US$9m | US$894k | US$55m |
Dec 29 2018 | n/a | n/a | US$46m |
Sep 29 2018 | n/a | n/a | US$21m |
Jun 30 2018 | n/a | n/a | US$23m |
Mar 31 2018 | US$8m | US$858k | US$46m |
Compensation vs Market: Chris's total compensation ($USD10.69M) is above average for companies of similar size in the German market ($USD2.47M).
Compensation vs Earnings: Chris's compensation has increased by more than 20% in the past year.
CEO
Chris Simon (59 yo)
7.9yrs
Tenure
US$10,686,395
Compensation
Mr. Christopher A. Simon, also known as Chris, has been the Chief Executive Officer and President of Haemonetics Corporation since May 16, 2016 and has been its Director since May 2016. He joined Haemoneti...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, President & Director | 7.9yrs | US$10.69m | 0.40% $ 16.3m | |
CFO, Executive VP & Financial Officer | 2yrs | US$3.76m | 0.0037% $ 152.1k | |
Executive VP & CTO | 4yrs | US$2.33m | 0.011% $ 452.6k | |
Executive VP | 7.1yrs | US$2.99m | 0.039% $ 1.6m | |
Executive Vice President of Global Manufacturing & Supply Chain | 5.7yrs | US$2.34m | 0.020% $ 799.8k | |
VP, Chief Accounting Officer & Principal Accounting Officer | 1.5yrs | no data | no data | |
Senior Director of Investor Relations | 4.5yrs | no data | no data | |
Senior Vice President of Strategy & Corporate Development | less than a year | no data | no data | |
Senior VP & Chief Human Resources Officer | 2.7yrs | no data | 0.016% $ 635.0k | |
Senior VP & Chief Medical Officer | less than a year | no data | no data | |
President of Global Hospital | 4.6yrs | US$2.48m | 0.032% $ 1.3m | |
Senior Vice President of Global Quality Assurance | 2.8yrs | no data | no data |
3.4yrs
Average Tenure
53.5yo
Average Age
Experienced Management: HAZ's management team is considered experienced (3.4 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, President & Director | 7.6yrs | US$10.69m | 0.40% $ 16.3m | |
Independent Director | 6.5yrs | US$284.95k | 0.035% $ 1.4m | |
Independent Director | 4yrs | US$272.95k | 0.016% $ 665.7k | |
Independent Chairman | 6.3yrs | US$439.95k | 0.024% $ 985.8k | |
Independent Director | 5yrs | US$269.95k | 0.019% $ 784.7k | |
Independent Director | 18.3yrs | US$269.95k | 0.032% $ 1.3m | |
Independent Director | 9.8yrs | US$292.95k | 0.035% $ 1.4m | |
Independent Director | 2.7yrs | US$272.95k | 0.011% $ 467.4k | |
Member of Scientific Advisory Council | no data | no data | no data | |
Member of Scientific Advisory Council | no data | no data | no data | |
Member of Scientific Advisory Council | no data | no data | no data | |
Member of Scientific Advisory Council | no data | no data | no data |
6.4yrs
Average Tenure
69yo
Average Age
Experienced Board: HAZ's board of directors are considered experienced (6.4 years average tenure).